NFKB1 and leukemia: Recently, CDA-2 was found to inhibit activation of NF-κB in human leukemia and myelodysplastic syndromes (MDS) cell lines in vitro through an impact on NF-κB nuclear translocation by affecting IkBα phosphorylation and degradation [3], [6].